Condition: T2DM (Type 2 Diabetes Mellitus) · Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
This description comes directly from the study's public registry record.
Xiaofen Qian · +86-0571-89908582 · qianxiaofen@eastchinapharm.com
Wanting Zhang · +86-0571-89905517 · zhangwanting@eastchinapharm.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07244003